Zydus Lifesciences Q2 FY27 Earnings Call: Revenue Jumps 29%, Saroglitazar US Launch Set For March 2027 (ZYDUSLIFE)

Broad-Based Growth With Margin Discipline

• Rs.79.1 billion consolidated revenue — up 29% YoY in Q2 FY 2026-2027; EBITDA at Rs.18.9 billion with 24% margin (adjusted margin up 150 bps excluding US Saroglitazar launch-related investments); net profit at Rs.9.3 billion.
• Net debt/EBITDA at 0.62x — as of September 30, 2026; net debt reduced to Rs.5,200 crore in Q2 FY 2026-2027 from Rs.5,900 crore in Q1 FY 2026-2027, with cash continuing to be used to pay down debt per CFO Tushar Shroff.
• Branded business at 57% of consolidated revenue — up 150 bps sequentially in Q2 FY 2026-2027; management reiterated a medium-term aspiration (period unspecified) for branded to reach two-thirds of consolidated revenue.
• 24%+ EBITDA margin on track for FY27 — management stated it is on track to deliver in line with its FY 2026-2027 expectations despite strategic investments ahead of the upcoming US Saroglitazar launch.
• Gross margin mix headwind — despite US improvement including the Rolvedon launch, margins did not improve commensurately because high-growth wellness carries gross margins not in the 70s, and significant high-gross-margin products declined, offsetting gains.

India Outpacing the IPM; International Up 33%

• India branded formulations +19% YoY — in Q2 FY 2026-2027 (20% YoY in H1 FY 2026-2027), outpacing the IPM; secondary sales up 20% YoY with volume and new products contributing ~two-thirds of growth.
• Share gains across eight therapies — cardiology, diabetology, respiratory, dermatology, GI, anti-infectives, oncology and nephrology, with oncology leadership retained; chronic and sub-chronic contribution at 56.9% per AWACS MAT September 2026, up 450 bps over the last 4 years.
• IPM outlook — management expects the IPM to grow 10-11% (period unspecified) and Zydus to grow 200-400 bps consistently above the IPM going forward (period unspecified); IPM itself had base issues due to GST and other factors in Q1-Q2 FY 2026-2027.
• International formulations at Rs.10 billion — up 33% YoY in Q2 FY 2026-2027 with broad-based growth via a therapy-led emerging markets strategy and European portfolio expansion.
• Europe dip is seasonal — the sharp QoQ decline in Q2 FY 2026-2027 reflects July-August summer holidays, a lean period in Europe.

Rolvedon Lifts Specialty; Base Business Rebounds

• North America revenue at Rs.33.1 billion — up 21% YoY and 7% QoQ in Q2 FY 2026-2027; US business reported ~$347-350 million (management also referenced a ~$250 million US revenue base for guidance purposes), driven by base business volume expansion and US specialty scale-up.
• Specialty at 16% of US revenues — up ~550 bps sequentially in Q2 FY 2026-2027, underscoring the transformation beyond generics toward 505(b)(2), rare disease and biologics; Rolvedon (added via the Assertio Holdings acquisition) drove the sequential specialty jump with better traction on Sentinel also contributing.
• Rolvedon trajectory — contribution expected to remain stable over Q3-Q4 FY 2026-2027, with a possible bump up again in 6-8 quarters (~Q4 FY 2027-2028 to Q2 FY 2028-2029).
• 4 ANDAs filed, 12 approvals, 5 launches — during Q2 FY 2026-2027; first generic version of RioCigat tablets launched in October 2026, with only two specialty distributors in the market and both working with Zydus.
• 15-20 launches guided — over the next 2-3 quarters (roughly Q3 FY 2026-2027 through Q1 FY 2027-2028), comprising ANDAs and 505(b)(2)/FTF products; US growth momentum expected to sustain for at least Q3-Q4 FY 2026-2027.
• Transdermal patches capacity crunch — market demand is 50% higher than currently served volumes as of Q2 FY 2026-2027; additional capacity will take "at least a year" (FY 2027-2028 at the earliest) and could double at that point.
• FY 2026-2027 US guidance reiterated — single-digit constant-currency growth on the high FY 2025-2026 base, with the Mira competition impact already factored in.

US Launch Ahead; Long Ramp, Modest Share Targets

• November 2026 goal date for Saroglitazar — management sees "potentially a goal date approval" if no further last-minute queries emerge, with remaining queries largely on labeling; commercial launch expected in March 2027 (Q4 FY 2026-2027) as a December year-end launch is not practical.
• ~Rs.115-120 crore already spent — on Saro commercialization as of Q2 FY 2026-2027; management expects commercial expense of ~$100 million every year (period unspecified), inclusive of pre-launch costs, with spend growing through Q3-Q4 FY 2026-2027.
• 20% patient share goal — as third-to-market entrant, the company's current goal is 20% patient share (period unspecified), explicitly not aiming to equal or beat the two competitors already in the market; management guided no meaningful revenue in FY 2027-2028, revenue starting FY 2028-2029 and "more realistically" FY 2029-2030, targeting only a 10-12% share by FY30 (FY 2029-2030) with significant share gained by 2033-34, sustained until IP expiry.
• MASH Phase 3 not being pursued — management stated a biopsy-led trial is "almost impossible to do anymore", making the asset not a licensing candidate either; the Phase 2B trial met its primary endpoint (resolution of steatohepatitis with no worsening of fibrosis at 52 weeks), and new Phase 3 PBC analysis was presented at ACG 2026.
• Palbociclib (Ibrance generic) — management estimates a September-October 2027 launch (Q2/Q3 FY 2027-2028) with 6 months of exclusivity; an earlier launch is not expected despite the pending pediatric exclusivity determination.
• Keytruda biosimilar under USFDA review — the BLA developed by partner Formicon is the first publicly announced Keytruda biosimilar filing accepted for review in the US; economics will be a profit-sharing arrangement between Zydus and Formicon; management declined to size the opportunity (brand is a $30+ billion-revenue biologics) pending launch timing and competitor count.
• R&D intensity at ~8-8.5% of sales — run-rate of ~Rs.650 crore per quarter in FY 2026-2027; of ~30 products filed, only ~10-12 are plain vanilla generics; $70-80 million (close to $100 million) to be spent over a period of time (period unspecified) on late-stage clinical programs including ALS Phase 2B in the US and Desidustat for sickle cell anemia.

H2 Flat as Taro Spend Rises; Deleveraging Continues

• H2 FY 2026-2027 margin guided similar to H1 — MD Sharvil Patel guided to a similar EBITDA margin in H2 (H1 FY 2026-2027 stood at 24% per the press release), stating that Taro spend will also go up in the second half.
• Full-year FY 2026-2027 EBITDA margin guidance of 24% maintained — per management on the call.
• Other expenses guided at Rs.2,000-2,050 crores — excluding R&D spend and Saroglitazar/ZTI commercialization cost (period unspecified); Q2 FY 2026-2027 other expenses ex-R&D and ex-ZTI showed marginal sequential degrowth; personnel expenses (ex-R&D) declined marginally QoQ but grew YoY on trailing-year acquisitions.
• D&A step-up — the sharp Q2 FY 2026-2027 increase includes acquisition-related amortization (including the Mira Vangron licensing deal); CFO expects the current run-rate, with a marginal increase as CWIP is capitalized, to continue up to September 2027, extending into FY 2027-2028.
• Comfortable operating up to 1x net debt/EBITDA — standing guidance per CFO Tushar Shroff; capex and investment cycle seeing an uptick as the company builds for growth over the next 5 years (through ~FY 2031-2032).
• Acquisition payback — CCL expected to turn accretive very soon; Amplitude positioned as a long-term platform investment; Rolvedon profitable from day one.

No FY28 Guidance Yet; FDA Observations Contained

• No FY 2027-2028 guidance exists yet — guidance has been given only till FY27; the FY28 outlook may be shared in Q4 FY 2026-2027; management flagged a good pipeline (Palbociclib launch and other new products) plus significant upside from patches and others, characterized as a long-term rather than short-term opportunity.
• USFDA inspections at two sites — SEZ 2 Ahmedabad (1 observation) and Moraiya (5 observations); management said Moraiya contributes less than 30% of US revenue (as of Q2 FY 2026-2027), has responded to the FDA, received 1 transdermal approval post-audit on October 21, 2026, and does not see facility concerns in most pending CRLs; the specific nature of the observations was not disclosed.
• Vaccines to double — management expects the business to double from the current annualized run rate of Rs.450 crores (as of Q2 FY 2026-2027) over the next 3-4 years (by FY 2029-2030 to FY 2030-2031); WHO registrations and pre-qualifications have started, with a decent share of upcoming rabies, TCV and MR tenders expected.
• Biosimilars scaling globally — India biosimilar revenues have crossed Rs.1,000+ crores (as of Q2 FY 2026-2027) with nivolumab a standout; from FY 2027-2028 onwards management expects global biosimilar revenues across the US, Mexico, South Asia and Latin America; semaglutide expected to add meaningfully to ex-India revenues over the next 3-4 years (by FY 2029-2030 to FY 2030-2031), explicitly excluding Pembrolizumab from that estimate.
• Bolt-on M&A only — MD Sharvil Patel said the strategy remains focused on bolt-on acquisitions with one med-tech platform deal already done, but the company sees no big-ticket acquisitions at this stage.
• Cabometyx (cabozantinib) litigation ongoing — the analyst characterized the partnered product as a late opportunity (~2030-31); management said other filings are possible and it will comment further once the appeals court decision comes.